

Table 2. Incremental cost per life saved for baseline data and following one way sensitivity analysis (Number of lives saved as the final outcome measure)

	Incremental cost per life saved(LKR/Life saved)	
	0-10hrs	10-24hrs
Baseline results	Not applicable [‡]	316,182
One way sensitivity analysis results		
<i>Increasing by 50%</i>		
NAC deaths	Not applicable [‡]	469,173
NAC cost	Not applicable [‡]	565,805
Methionine deaths	Not applicable [‡]	173,147
Methionine cost	Not applicable [‡]	265,107
<i>Decreasing by 50%</i>		
NAC deaths	Not applicable [‡]	238,432
NAC cost	Not applicable [‡]	55,312
Methionine deaths	Not applicable [‡]	1,818,046
Methionine cost	Not applicable [‡]	366,486
<i>Upper confidence interval(CI)</i>		
NAC deaths	<u>Dominance for methionine</u> [†]	909,023
NAC hepatotoxicity	Not applicable [‡]	445,229
Methionine deaths	5,365,130	73,456
Methionine hepatotoxicity	Not applicable [‡]	94,349
<i>Lower confidence interval(CI)</i>		
NAC deaths	Not applicable [‡]	229,648
NAC hepatotoxicity	Not applicable [‡]	268,907

Methionine deaths	Not applicable [‡]	<u>Dominance for methionine</u> [†]
Methionine hepatotoxicity	Not applicable [‡]	836,480

[‡] The outcome resulted from alternative interventions were similar therefore cost effectiveness ratios were not calculated.

[†] Methionine shows strong dominance for a decision as the incremental effectiveness was lower while the incremental cost is higher for NAC (methionine saves more lives at a lower cost).